Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

Inclusion Criteria:

• Patients aged 20 years or older at the time of consent acquisition

• Patients with binocular intensity myopia (myopia of -6.0 diopter (D) or more) orpatients with axial length (26 mm) or more equivalent to -6.0 D

• Corrected characters of the test eye patients with visual acuity of less than 60characters (equivalent to decimal visual acuity 0.32)

• Patients diagnosed with binocular myopic chorioretinal atrophy and having atrophy of 1 papillary diameter (1.5 mm) or more in the area within 2 papillary diameter (3.0mm) including the fovea centralis in the subject eye

• Patients without active choroidal neovascularization

Exclusion Criteria:

• Patients with abnormal findings that pose a problem in clinical trial participationin screening tests.

• Patients with positive hepatitis B surface (HBs) antigen, Hepatitis C virus (HCV)antibody, Human immunodeficiency virus (HIV) antibody, Human T-lymphotropic virustype 1 (HTLV-1) antibody, syphilis serum reaction

• Patients with allergies to human serum albumin antibiotics, trypsin

• Patients with eye infections

• Patients with other retinal diseases (diabetic retinopathy, hypertensiveretinopathy, vascular occlusion)

• Patients with confirmed optic nerve atrophy

• Patients with glaucoma who cannot control intraocular pressure

• Patients with findings associated with myopic traction macular disease (apparentposterior macular tumor, vitreous macular traction, retinal separation, macular holedetachment, macular hole)

• Patients with atrophy in all areas of the circle within 3 papilla diameter (4.5 mm) (9.0 mm in diameter) from the fovea

• Patients with corrected visual acuity of control eye 0.08 or less

• Patients with severe blood disorders, heart failure, liver disorders, and renaldisorders

• Patients diagnosed with malignant tumor within 5 years or patients requiringtreatment

• Pregnant women, lactating women, patients wishing to become pregnant during thetrial period

• Patients who cannot discontinue anticoagulants or antiplatelet drugs before thetrial

• Patients with drug addiction or alcoholism

• Patients receiving treatment with vascular endothelial growth factor inhibitor orphotodynamic therapy within 4 months prior to transplantation for test eye or 2months for reference eye.

• Patients who underwent eye surgery (excluding lens reconstruction) within 3 monthsbefore transplantation. In the case of cataract surgery, if 7 days or more havepassed since surgery and postoperative inflammation is stable, registration ispossible.